|Bid||3.0100 x 2200|
|Ask||3.8900 x 1000|
|Day's Range||3.2800 - 3.4500|
|52 Week Range||3.2100 - 7.6000|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investing in biotech stocks can provide true binary opportunities. If the drug succeeds, small-cap biotech stocks easily become multi-baggers. Warning! GuruFocus has detected 2 Warning Signs with FOMX.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Anyone researching Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) might want to consider the historical volatility of the share pr...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
A look at the shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials. The treatment, code-named FMX103 and made up of an antibiotic commonly used to treat infections, significantly reduced inflammatory lesions, compared to a foam without the antibiotic, minocycline. The two late-stage studies enrolled over a thousand patients suffering from papulopustular rosacea, which causes lesions to break out on the face, and the mostly commonly reported side effects were upper respiratory tract infections, the company said.
If you own shares in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Genomic ...
Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading. FMX101, a topical minocycline foam, showed significant reduction in the number of inflammatory lesions in the trial which enrolled 1,507 patients, the company said. "If approved, we believe FMX101 would be the first topical minocycline product available for patients in the United States," Chief Executive David Domzalski said in a statement.
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the UnitedRead More...
Investors in Foamix Pharmaceuticals (FOMX) need to pay close attention to the stock based on moves in the options market lately.
Foamix (FOMX) delivered earnings and revenue surprises of 22.03% and -12.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rehovot, Israel-based company said it had a loss of 46 cents. The acne treatment developer posted revenue of $964,000 in the period. Foamix shares have decreased 4 percent since ...